RU2544169C2 - Method for intestevit encapsulation - Google Patents

Abstract

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine and consists in a method for intestevit encapsulation. Implementing the method involves dissolving 100 mg of intestevit in 1 ml of dioxane, or dimethylsulphoxide, or dimethylformamide, dispersing the prepared mixture in a sodium carboxymethylcellulose solution in acetone containing 300 ml of the above polymer in the presence of 0.01 g of the preparation E472 while stirring, adding 1 ml of distilled water, and filtering and drying the prepared suspension.

EFFECT: simplifying and fastening the process of microcapsules obtaining, reducing the loss accompanying the microencapsulation process.

3 ex

Description

The invention relates to the field of encapsulation of intentional, in particular the production of microcapsules.

Previously known methods for producing microcapsules of drugs. So, in Pat. 2092155 IPC А61К 047/02, А61К 009/16, published October 10, 1997, Russian Federation, a method of microencapsulation of drugs based on the use of ultraviolet radiation is proposed.

The disadvantages of this method are the duration of the process and the use of ultraviolet radiation, which can affect the process of formation of microcapsules.

In US Pat. 2091071 IPC A61K 35/10, Russian Federation, published 09/27/1997, a method for producing the preparation by dispersion in a ball mill to obtain microcapsules is proposed.

The disadvantage of this method is the use of a ball mill and the duration of the process.

In US Pat. 2101010 IPC A61K 9/52, A61K 9/50, A61K 9/22, A61K 9/20, A61K 31/19, Russian Federation, published January 10, 1998, a chewing form of the drug with a taste mask is proposed, which has the properties of a controlled release of the drug contains microcapsules with a size of 100-800 microns in diameter and consists of a pharmaceutical core with crystalline ibuprofen and a polymer coating comprising a plasticizer flexible enough to withstand chewing. The polymer coating is a methacrylic acid based copolymer.

The disadvantages of the invention: the use of a copolymer based on methacrylic acid, as these polymer coatings can cause cancerous tumors; complexity of execution; the duration of the process.

In US Pat. 2173140 IPC A61K 009/50, A61K 009/127, Russian Federation, published September 10, 2001. A method for producing silicon organolipid microcapsules using a rotary-cavitation unit with high shear forces and powerful sonar acoustic and ultrasonic dispersion ranges is proposed.

The disadvantage of this method is the use of special equipment - a rotary cavitation unit, which has an ultrasonic effect, which affects the formation of microcapsules and can cause adverse reactions due to the fact that ultrasound destructively affects polymers of a protein nature, therefore, the proposed method is applicable when work with polymers of synthetic origin.

In US Pat. 2359662 IPC A61K 009/56, A61J 003/07, B01J 013/02, A23L 001/00, published June 27, 2009, Russian Federation, a method for producing microcapsules using spray cooling in a Niro spray cooling tower under the following conditions: inlet air temperature 10 ° C; outlet air temperature 28 ° C; spray drum rotation speed of 10,000 rpm. The microcapsules of the invention have improved stability and provide controlled and / or prolonged release of the active ingredient.

The disadvantages of the proposed method are the duration of the process and the use of special equipment, a set of certain conditions (air temperature at the inlet 10 ° C, air temperature at the outlet 28 ° C, rotation speed of the spray drum 10,000 rpm).

The closest method is the method proposed in US Pat. 2134967 IPC A01N 53/00, A01N 25/28, published August 27, 1999, Russian Federation (1999). A solution of a mixture of natural lipids and a pyrethroid insecticide in a weight ratio of 2-4: 1 in an organic solvent is dispersed in water, which simplifies the microencapsulation method.

The disadvantage of this method is dispersion in an aqueous medium, which makes the proposed method inapplicable for producing microcapsules of water-soluble preparations in water-soluble polymers.

The technical task is to simplify and accelerate the process of obtaining microcapsules, reducing losses when receiving microcapsules (increase in yield by mass).

The solution to the technical problem is achieved by the method of encapsulation of Intenstevite, characterized in that sodium carboxymethyl cellulose is used as the shell of the microcapsules when they are obtained by the physicochemical precipitation method with a non-solvent using acetone as a precipitant, the production process is carried out without special equipment.

A distinctive feature of the proposed method is the use of sodium carboxymethyl cellulose as the shell of intensenite microcapsules as their core, as well as the use of acetone as a precipitant.

The result of the proposed method is the production of Intenstevit microcapsules in sodium carboxymethyl cellulose at 25 ° C for 20 minutes. The output of microcapsules is more than 90%.

EXAMPLE 1. Obtaining microencapsules of Intenstevit with dissolution of the drug in dioxane, core / polymer ratio 1: 3 100 mg of Intenstevit is dissolved in 1 ml of dioxane and the mixture is dispersed in a solution of sodium carboxymethyl cellulose in acetone containing the indicated 300 mg of polymer in the presence of 0.01 g of the drug E472 s (glycerol ester with one or two molecules of food fatty acids and one or two molecules of citric acid, moreover, citric acid, as a tribasic acid, can be esterified with other glycerides and as an acid with other acids GOVERNMENTAL acids, free acid groups may be neutralized with sodium) while stirring 1000 rpm / sec. Then pour 1 ml of distilled water. The resulting suspension is filtered and dried at room temperature.

Received 0.356 g of a white with a yellowish tinge of powder. The yield was 89%.

EXAMPLE 2. Obtaining microcapsules of intensey with dissolution of the drug in dimethyl sulfoxide (DMSO), the ratio of core / polymer 1: 3

100 mg of Intenstevit is dissolved in 1 ml of DMSO and the resulting mixture is dispersed in a solution of sodium carboxymethyl cellulose in acetone containing the indicated 300 mg of polymer in the presence of 0.01 g of the preparation E472 s with stirring 1000 rps. Then pour 1 ml of distilled water. The resulting suspension is filtered and dried at room temperature.

Received 0.356 g of a white with a yellowish tinge of powder. The yield was 89%.

EXAMPLE 3. Obtaining microencapsules of itenstevite with dissolution of the drug in dimethylformamide (DMF), the ratio of core / polymer 1: 3

100 mg of itenstevit is dissolved in 1 ml of DMF and the resulting mixture is dispersed in a solution of sodium carboxymethyl cellulose in acetone containing the indicated 300 mg of polymer in the presence of 0.01 g of the preparation E472 s with stirring 1000 rps. Then pour 1 ml of distilled water. The resulting suspension is filtered and dried at room temperature.

Received 0.356 g of a white with a yellowish tinge of powder. The yield was 89%.

Itenstevite microcapsules were obtained by the physicochemical non-solvent precipitation method using acetone as a precipitant, which helps to increase the yield and accelerates the microencapsulation process. The process is simple to execute and lasts for 20 minutes, does not require special equipment.

The proposed technique is suitable for the veterinary industry due to minimal losses, speed, ease of obtaining and isolation of microcapsules.

Claims (1)

Intestevitis encapsulation method, characterized in that 100 mg of intestine is dissolved in 1 ml of dioxane, or dimethyl sulfoxide, or dimethylformamide, the mixture is dispersed in a solution of sodium carboxymethyl cellulose in acetone containing 300 ml of the specified polymer in the presence of 0.01 g of the preparation E472 with stirring 1 ml of distilled water is added, the resulting suspension is filtered off and dried.